Profile data is unavailable for this security.
About the company
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.
- Revenue in USD (TTM)0.00
- Net income in USD-15.37m
- Incorporated1998
- Employees29.00
- LocationCassava Sciences Inc6801 N CAPITAL OF TEXAS HIGHWAYBUILDING 1; SUITE 300AUSTIN 78731United StatesUSA
- Phone+1 (512) 501-2444
- Fax+1 (512) 614-0414
- Websitehttps://www.cassavasciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharvaris NV | 0.00 | -121.56m | 1.15bn | 82.00 | -- | 3.24 | -- | -- | -2.55 | -2.55 | 0.00 | 6.56 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -74.89m | 1.15bn | 40.00 | -- | 3.88 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Ardelyx Inc | 251.85m | -72.58m | 1.16bn | 267.00 | -- | 7.33 | -- | 4.60 | -0.3113 | -0.3113 | 1.08 | 0.6682 | 0.7664 | 3.76 | 5.22 | 943,254.70 | -22.09 | -46.14 | -26.72 | -57.32 | 85.16 | 88.15 | -28.82 | -240.87 | 3.87 | -5.94 | 0.3888 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Applied Therapeutics Inc | -211.00k | -187.31m | 1.18bn | 37.00 | -- | 202.22 | -- | -- | -1.53 | -1.53 | -0.0017 | 0.0506 | -0.0028 | -- | -- | -8,440.00 | -246.85 | -140.37 | -- | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Bicara Therapeutics Inc | 0.00 | -64.84m | 1.18bn | 32.00 | -- | -- | -- | -- | -1.25 | -1.25 | 0.00 | 3.72 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
| Zymeworks Inc | 62.20m | -113.67m | 1.20bn | 294.00 | -- | 3.31 | -- | 19.27 | -1.51 | -1.51 | 0.8306 | 5.23 | 0.1192 | -- | 1.37 | 228,672.80 | -21.79 | -22.58 | -25.64 | -26.90 | -- | -- | -182.75 | -91.17 | -- | -- | 0.00009 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Aurinia Pharmaceuticals Inc | 220.36m | -22.55m | 1.21bn | 300.00 | -- | 3.13 | -- | 5.51 | -0.1582 | -0.1582 | 1.53 | 2.71 | 0.3991 | 0.7854 | 5.92 | 734,536.70 | -4.08 | -25.97 | -4.74 | -28.24 | 87.25 | -- | -10.23 | -137.64 | 5.11 | -- | 0.1725 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| CareDx Inc | 312.78m | -143.56m | 1.25bn | 635.00 | -- | 4.54 | -- | 4.00 | -2.70 | -2.70 | 5.95 | 5.15 | 0.6395 | 5.75 | 5.29 | 492,559.10 | -29.35 | -17.54 | -34.84 | -20.85 | 65.77 | 65.50 | -45.90 | -27.78 | 3.87 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
| Arcutis Biotherapeutics Inc | 138.71m | -195.54m | 1.27bn | 296.00 | -- | 8.10 | -- | 9.15 | -1.79 | -1.79 | 1.23 | 1.34 | 0.3799 | 1.04 | 3.49 | 468,608.10 | -53.55 | -65.64 | -75.79 | -71.72 | 89.57 | -- | -140.97 | -1,513.03 | 2.38 | -6.19 | 0.5664 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -15.37m | 1.30bn | 29.00 | -- | 6.87 | -- | -- | -0.4054 | -0.4054 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -6.97 | -30.74 | -8.35 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -82.83m | 1.31bn | 52.00 | -- | 4.27 | -- | -- | -1.93 | -1.93 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -26.91 | -42.26 | -28.35 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Vir Biotechnology Inc | 78.62m | -533.34m | 1.36bn | 587.00 | -- | 1.09 | -- | 17.29 | -3.92 | -3.92 | 0.5794 | 9.08 | 0.0444 | -- | -- | 133,931.90 | -30.10 | -0.6081 | -32.71 | -0.7192 | 98.78 | -- | -678.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Kura Oncology Inc | 0.00 | -197.55m | 1.37bn | 142.00 | -- | 3.22 | -- | -- | -2.36 | -2.36 | 0.00 | 5.45 | 0.00 | -- | -- | 0.00 | -41.48 | -26.04 | -44.66 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0219 | -- | -- | -- | -12.36 | -- | -- | -- |
| Upstream Bio Inc | 2.22m | -54.81m | 1.44bn | 38.00 | -- | -- | -- | 646.73 | -1.07 | -1.07 | 0.0433 | 4.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,823.82 | -- | -- | -- | 0.00 | -- | 96.37 | -- | -60.28 | -- | -- | -- |
| Novavax Inc | 987.67m | -294.33m | 1.44bn | 1.54k | -- | -- | -- | 1.46 | -2.76 | -2.76 | 7.41 | -2.70 | 0.5638 | 21.98 | 4.63 | 640,095.30 | -16.80 | -46.06 | -78.53 | -269.57 | 63.67 | -- | -29.80 | -75.94 | 1.03 | -18.79 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
Data as of Nov 12 2024. Currency figures normalised to Cassava Sciences Inc's reporting currency: US Dollar USD
20.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.89m | 6.03% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.56m | 5.35% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.18m | 2.45% |
| Geode Capital Management LLCas of 30 Jun 2024 | 967.30k | 2.02% |
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 690.92k | 1.44% |
| Gallacher Capital Management LLCas of 30 Jun 2024 | 582.49k | 1.21% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 371.71k | 0.78% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 351.37k | 0.73% |
| National Bank Financial, Inc.as of 30 Jun 2024 | 223.60k | 0.47% |
| Clear Creek Financial Management LLCas of 30 Sep 2024 | 153.53k | 0.32% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
